Antibacterial responses of retinal Müller glia: production of antimicrobial peptides, oxidative burst and phagocytosis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Singh PK; Shiha MJ; Kumar A; Kumar A
  • Source:
    Journal of neuroinflammation [J Neuroinflammation] 2014 Feb 18; Vol. 11, pp. 33. Date of Electronic Publication: 2014 Feb 18.
  • Publication Type:
    Journal Article; Research Support, N.I.H., Extramural
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101222974 Publication Model: Electronic Cited Medium: Internet ISSN: 1742-2094 (Electronic) Linking ISSN: 17422094 NLM ISO Abbreviation: J Neuroinflammation Subsets: MEDLINE
    • Publication Information:
      Original Publication: [London] : BioMed Central, c2004-
    • Subject Terms:
      Anti-Bacterial Agents/*pharmacology ; Ependymoglial Cells/*drug effects ; Gene Expression Regulation, Bacterial/*physiology ; Phagocytosis/*physiology; Analysis of Variance ; Antimicrobial Cationic Peptides/genetics ; Antimicrobial Cationic Peptides/therapeutic use ; Cell Line, Transformed ; Colony Count, Microbial ; Gene Expression Regulation, Bacterial/drug effects ; Hepcidins/genetics ; Humans ; Nitrites/metabolism ; Reactive Oxygen Species/metabolism ; Staphylococcus aureus/physiology ; beta-Defensins/genetics ; Cathelicidins
    • Abstract:
      Background: We have previously shown that, in response to microbial infection, activated Müller glia secrete inflammatory cytokines/chemokines and exhibit antimicrobial properties. The aim of this study is to understand the mechanisms and the key components involved in this response.
      Methods: Immortalized human retinal Müller glia (MIO-M1 cells) were challenged with Staphylococcus (S) aureus, the leading cause of severe intraocular infection followed by RT2 profile PCR array analysis. The expression of human β-defensin 1 (HBD1), 2 (HBD2), 3 (HBD3), hepcidine and cathelicidin LL37 was checked by RT-PCR and quantified by Taqman qPCR. The expression of AMPs was confirmed at protein level by dot-blot analysis. The production of ROS was measured by dicholoro-dihydro-fluorescein diacetate (DCFH-DA) staining by flow cytometry as well as fluorescence microscopy. The level of nitric oxide (NO) was measured by measuring a stable metabolite, nitrite using the Griess reagent. In vitro killing assay was performed by Live/Dead BacLight staining as well as by dilution plating in suspension and adherent conditions following S. aureus infection. Phagocytosis was measured by CFU enumeration following infection.
      Results: PCR array data showed that, in comparison to uninfected control cells, bacterial challenge significantly (> two-fold) induced the expression of 26 genes involved in cytokine/chemokine, antimicrobials, Toll-like receptor, apoptotic, and NF-κB signaling. RT-PCR analysis showed time-dependent increased expression of HBD1, HBD2, HBD3, LL-37, and hepcidin mRNA in bacteria-challenged Müller glia. The expression of these antimicrobial molecules was also increased at the protein level in the culture supernatant, as detected by dot-blot analysis. Additionally, the bacteria-stimulated Müller glia were found to produce reactive oxygen (ROS) and reactive nitrogen (RNS) species. In vitro, killing assays revealed that Müller glia exhibited bactericidal activity against S. aureus in both adherent and suspension cultures. Furthermore, our data demonstrated that Müller glia can phagocytize and kill the bacteria in a time-dependent manner.
      Conclusions: These data suggest that retinal Müller glia behave like classical innate immune cells by producing a variety of antimicrobial molecules in response to bacterial challenge, suggesting their pivotal role in retinal innate defense.
    • References:
      J Leukoc Biol. 2005 Aug;78(2):338-44. (PMID: 15857941)
      Graefes Arch Clin Exp Ophthalmol. 2007 Jan;245(1):82-92. (PMID: 16598463)
      Infect Immun. 1995 Mar;63(3):1142-4. (PMID: 7868241)
      J Comp Neurol. 2008 Jul 10;509(2):225-38. (PMID: 18465787)
      Histol Histopathol. 2003 Oct;18(4):1205-18. (PMID: 12973689)
      Arch Ophthalmol. 2005 May;123(5):613-20. (PMID: 15883279)
      Infect Immun. 2012 Jun;80(6):2076-88. (PMID: 22431652)
      Crit Rev Immunol. 2013;33(2):119-35. (PMID: 23582059)
      Br J Ophthalmol. 2010 Nov;94(11):1523-7. (PMID: 20679078)
      Immunity. 2008 Nov 14;29(5):672-4. (PMID: 19006691)
      DNA Cell Biol. 2002 May-Jun;21(5-6):415-20. (PMID: 12167244)
      BMC Infect Dis. 2002 Sep 18;2:20. (PMID: 12238953)
      PLoS One. 2012;7(11):e49209. (PMID: 23166614)
      Biochem J. 2008 Apr 1;411(1):79-88. (PMID: 18042040)
      Ophthalmology. 1995 Nov;102(11):1696-701. (PMID: 9098264)
      Prog Retin Eye Res. 2012 Jul;31(4):316-31. (PMID: 22521570)
      Prog Retin Eye Res. 2014 May;40:94-123. (PMID: 24412518)
      J Biol Chem. 1997 May 16;272(20):13088-93. (PMID: 9148921)
      Prog Retin Eye Res. 2006 Jul;25(4):397-424. (PMID: 16839797)
      Ophthalmic Res. 2010;44(3):191-8. (PMID: 20829643)
      Nitric Oxide. 2012 Jun 30;27(1):25-31. (PMID: 22521523)
      Ophthalmology. 2009 Jun;116(6):1225.e1. (PMID: 19486799)
      Nature. 2011 Apr 28;472(7344):476-80. (PMID: 21525932)
      J Endod. 2010 Jun;36(6):1009-13. (PMID: 20478456)
      Ophthalmology. 1993 Oct;100(10):1468-74. (PMID: 8414406)
      Invest Ophthalmol Vis Sci. 1990 Jun;31(6):1047-55. (PMID: 2162333)
      BMC Cancer. 2006 Jun 23;6:163. (PMID: 16796735)
      PLoS One. 2012;7(1):e29830. (PMID: 22253793)
      J Leukoc Biol. 2007 Mar;81(3):632-41. (PMID: 17158608)
      J Immunol. 2011 Jun 15;186(12):7089-97. (PMID: 21602496)
      J Cataract Refract Surg. 2006 Mar;32(3):407-10. (PMID: 16631047)
      J Dermatol Sci. 2004 Apr;34(2):73-82. (PMID: 15033189)
      Indian J Med Res. 2013 Nov;138(5):609-19. (PMID: 24434316)
      Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6399-403. (PMID: 7604003)
      Peptides. 2011 Jul;32(7):1469-76. (PMID: 21693141)
      Ophthalmology. 2000 May;107(5):823-8. (PMID: 10811069)
      Lett Appl Microbiol. 2010 Feb;50(2):211-5. (PMID: 20002576)
      Jpn J Infect Dis. 2001 Dec;54(6):209-19. (PMID: 11862002)
      Biochem Biophys Res Commun. 2011 Feb 11;405(2):244-9. (PMID: 21219868)
      Retina. 2009 May;29(5):601-5. (PMID: 19357558)
      J Immunol. 2004 Apr 15;172(8):4987-94. (PMID: 15067080)
      Curr Opin Ophthalmol. 2010 May;21(3):178-83. (PMID: 20375895)
      J Infect Dis. 2010 Jan 15;201(2):255-63. (PMID: 19995266)
      Mol Microbiol. 2008 Nov;70(4):953-64. (PMID: 18811727)
      Trends Neurosci. 1996 Aug;19(8):307-12. (PMID: 8843598)
      Clin Infect Dis. 1995 Oct;21 Suppl 2:S162-5. (PMID: 8845445)
      Prog Retin Eye Res. 2007 Mar;26(2):189-203. (PMID: 17236804)
      Clin Infect Dis. 2012 Apr;54 Suppl 3:S229-32. (PMID: 22431853)
      Nat Rev Immunol. 2003 Sep;3(9):710-20. (PMID: 12949495)
      Infect Immun. 2008 Sep;76(9):4176-82. (PMID: 18591225)
      Clin Microbiol Rev. 1997 Jan;10(1):1-18. (PMID: 8993856)
    • Grant Information:
      R01 EY19888 United States EY NEI NIH HHS
    • Accession Number:
      0 (Anti-Bacterial Agents)
      0 (Antimicrobial Cationic Peptides)
      0 (Hepcidins)
      0 (Nitrites)
      0 (Reactive Oxygen Species)
      0 (beta-Defensins)
      0 (Cathelicidins)
    • Publication Date:
      Date Created: 20140220 Date Completed: 20140916 Latest Revision: 20221207
    • Publication Date:
      20240829
    • Accession Number:
      PMC3937076
    • Accession Number:
      10.1186/1742-2094-11-33
    • Accession Number:
      24548736